Hypoxia imaging in lung cancer patients utilizing62Cu-ATSM-PET/CT with reference to histopathology.

Hypoxia imaging in lung cancer patients utilizing62Cu-ATSM-PET/CT with reference to histopathology. - Hypoxia imaging in lung cancer patients utilizing62Cu-ATSM-PET/CT with reference to histopathology.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006898

Enrollment

Registered

2011-12-17

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

ATSM PET CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The case who was diagnosed as primary lung cancer either pathologically or cytologically. 2) The case who was scheduled to receive a curative resection. 3) The case to whom iodine contrast media can be injected. 4) The case who gave the written consent to join the study. 5) The case whose PS is between 0 and 2, the case who suffers from a serious illness except malignancy and the case who will become pregnant.

Exclusion criteria

Exclusion criteria: 1) The case who is difficult to be included in the study due to psychological disorder and so on. 2) The case to whom the test agent cannot be injected due to iodine allergy and so on. 3) The case who is judged by the physician in charge not to be included in the study.

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
The accumulation of ATSM at the tumor	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026